DRL

A high base, continued price erosion in the US market, modest sales growth in key markets such as North America, and weak profitability are likely to mar the overall earnings of the…

…

The Indian market closed in the red for the third consecutive day on Wednesday. The S&P BSE Sensex fell by nearly 400 points while the Nifty50 closed below 16,000 levels. Sectorally,…

Nifty futures on the Singapore Exchange traded 20 points, or 0.12 per cent lower at 16,207.5, signaling that Dalal Street was headed for a positive start on Monday. Here are a dozen stocks…

Dr. Reddy’s on Friday announced that it has acquired a portfolio of branded and generic injectable products from Deer Park, Illinois, based Eton Pharmaceuticals. Under the terms of the…

Friday’s move compliments data points on the indices. We also saw a blend of short covering as well as long built up so there were so many large cap names which looked more formidable likes…

Foreign brokerage CLSA has downgraded to 'underperform' while Morgan Stanley has maintained its underweight stance on . On Dr Reddy's Labs (DRL), Morgan Stanley has an 'overweight' stance.…

Pharma major Dr. Reddy’s Laboratories reported consolidated net profit surged to ₹709.3 crore in the December quarter on improved sales in mainstay generics and a sharp decline in…

DRL gets rights to commercialise proposed trastuzumab biosimilar in select LatAm, S-E Asia markets. Pharma major Dr. Reddy’s Laboratories has entered into a partnership with Prestige…

Covaxin phase 2/3 studies have been completed for 2 to 17 years age group population and immunogenicity and safety data have been submitted to the Drugs Controller General of India (DCGI)…